Valuation : Harvard Bioscience, Inc.

Market Cap 36.51M 31.4M 29.53M 26.96M 50.42M 3.45B 50.58M 350M 135M 1.77B 137M 134M 5.63B P/E 2026 *
-4.12x
P/E 2027 * -17.2x
Enterprise Value 36.51M 31.4M 29.53M 26.96M 50.42M 3.45B 50.58M 350M 135M 1.77B 137M 134M 5.63B EV / Sales 2026 *
0.41x
EV / Sales 2027 * 0.39x
Free-Float
90.61%
Yield 2026 *
-
Yield 2027 * -
1 day+0.25%
1 week-1.11%
Current month-1.11%
1 month+23.96%
3 months+29.46%
6 months+45.82%
Current year+19.92%
1 week 7.85
Extreme 7.85
8.4
1 month 6.05
Extreme 6.05
8.4
Current year 4
Extreme 4
8.4
1 year 3.76
Extreme 3.755
9.4
3 years 2.81
Extreme 2.813
55.6
5 years 2.81
Extreme 2.813
82.9
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 2025-07-27
Director of Finance/CFO 63 2025-05-11
Chief Tech/Sci/R&D Officer - 2019-03-31
Director TitleAgeSince
Director/Board Member 52 2017-10-23
Director/Board Member 55 2025-06-01
Director/Board Member 52 2025-07-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26 Free

Chief Executive Officer

75,000 0.1677%
3/20/26 Free

Chief Financial Officer

30,000 0.0671%
3/17/26 Buy

Director

10,000 0.0224%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-1.11%+67.71%-81.77% 36.51M
-0.75%-0.54%+24.60%+15.45% 227B
-1.60%-2.76%+3.72%-18.54% 146B
-0.85%-2.70%-21.45%+23.38% 130B
+1.81%-1.04%-55.42%-11.30% 69.27B
+0.13%-0.94%+11.07%+18.15% 51.82B
-0.97%-1.30%-18.25%-15.08% 50.45B
+0.59%-1.76%+17.17%+29.76% 42.53B
-1.01%-1.27%+33.64%+51.45% 40.22B
-1.55%+2.15%+120.58%+37.37% 32.95B
Average -0.40%-0.73%+18.34%+4.89% 78.98B
Weighted average by Cap. -0.63%-1.41%+6.61%+9.86%

Financials

2026 *2027 *
Net sales 89.8M 77.23M 72.64M 66.31M 124M 8.49B 124M 861M 333M 4.35B 337M 330M 13.85B 94.55M 81.31M 76.48M 69.81M 131M 8.94B 131M 907M 351M 4.58B 355M 347M 14.59B
Net income -8.9M -7.65M -7.2M -6.57M -12.29M -842M -12.33M -85.36M -32.99M -431M -33.42M -32.69M -1.37B -2.2M -1.89M -1.78M -1.62M -3.04M -208M -3.05M -21.1M -8.16M -107M -8.26M -8.08M -339M
Net Debt - -
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
26-09-04 US$8.020 +0.25% 9,893
26-09-03 US$8.000 -2.44% 24,493
26-09-02 US$8.200 +1.99% 36,450
26-09-01 US$8.040 -0.86% 21,033
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.020USD
Average target price
7.500USD
Spread / Average Target
-6.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HBIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!